A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas

Genes Chromosomes and Cancer

Volumn 46, Issue 4, 2007, Pages 336-347

  Wang, Tongsheng ^b   Zhang, Xinmin ^a   Obijuru, Laura ^a   Laser, Jordan ^a   Aris, Virginie ^b   Lee, Peng ^a   Mittal, Khush ^a   Soteropoulos, Patricia ^b,c   Wei, Jian Jun ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ARTICLE; CANCER GENETICS; CANCER SUSCEPTIBILITY; CISTRON; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE CLUSTER; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC RISK; HMGA2 GENE; HUMAN; HUMAN TISSUE; LET 7 GENE; MICROARRAY ANALYSIS; MIR 197 GENE; MIR 21 GENE; MIR 23B GENE; MIR 29B GENE; MULTIGENE FAMILY; PRIORITY JOURNAL; RACE DIFFERENCE; RNA ANALYSIS; RNA GENE; TUMOR GENE; TUMOR VOLUME; UTERUS MYOMA;

CONTINENTAL POPULATION GROUPS; FEMALE; GENE EXPRESSION; HUMANS; LEIOMYOMA; MICRORNAS; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS;

EID: 33947104498     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20415     Document Type: Article

References (50)

1. Al-Hendy A, Salama SA. 2006a. Catechol-o-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig 13:136-144.
2. Al-Hendy A, Salama SA. 2006b. Ethnic distribution of estrogen receptor-α polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril 86:686-693.
3. Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T, Margalit H. 2005. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res 33:2697-2706.
4. Alvarez-Garcia I, Miska EA. 2005. MicroRNA functions in animal development and human disease. Development 132:4653-4662.
5. Amarzguioui M, Rossi JJ, Kim D. 2005. Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett 579:5974-5981.
6. Arslan AA, Gold LI, Mittal K, Suen TC, Belitskaya-Levy I, Tang MS, Toniolo P. 2005. Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum Reprod 20:852-863.
7. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. 2003. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am J Obstet Gynecol 188:100-107.
8. Bartholin L, Powers SE, Melhuish TA, Lasse S, Weinstein M, Wotton D. 2006. TGIF inhibits retinoid signaling. Mol Cell Biol 26:990-1001.
9. Bentwich I. 2005. Prediction and validation of microRNAs and their targets. FEBS Lett 579:5904-5910.
10. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. 2005. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793-1801.
11. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumicru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM. 2004. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 101:11755-11760.
12. Davis B. 2005. Uterine Leiomyoma Longitudinal Interventions Studies: The Fibroid Growth Study. Bethesda MD: NIH.
13. Farquhar CM, Steiner CA. 2002. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 99:229-234.
14. Flake GP, Andersen J, Dixon D. 2003. Etiology and pathogenesis of uterine leiomyomas: A review. Environ Health Perspect 111:1037-1054.
15. Garcia-Torres R, Cruz D, Orozco L, Heidet L, Gubler MC. 2000. Alport syndrome and diffuse leiomyomatosis. Clinical aspects, pathology, molecular biology and extracellular matrix studies. A synthesis. Nephrologie 21:9-12.
16. Graur D, Li WH. 2000. Fundamentals of Molecular Evolution, 2nd ed. 20-0210, Sinauer Associates, Inc., Sunderland, MA.
17. Gross KL, Neskey DM, Manchanda N, Weremowicz S, Kleinman MS, Nowak RA, Ligon AH, Rogalla P, Drechsler K, Bullerdiek J, Morton CC. 2003. HMGA2 expression in uterine leiomyomata and myometrium: Quantitative analysis and tissue culture studies. Genes Chromosomes Cancer 38:68-79.
18. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A. 2005. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102:19075-19080.
19. Hennig Y, Deichert U, Bonk U, Thode B, Bartnitzke S, Bullerdiek J. 1999. Chromosomal translocations affecting 12q14-15 but not deletions of the long arm of chromosome 7 associated with a growth advantage of uterine smooth muscle cells. Mol Hum Reprod 5:1150-1154.
20. Hennig Y, Rogalla P, Wanschura S, Frey G, Deichert U, Bartnitzke S, Bullerdiek J. 1997. HMGIC expressed in a uterine leiomyoma with a deletion of the long arm of chromosome 7 along with a 12q14-15 rearrangement but not in tumors showing del(7) as the sole cytogenetic abnormality. Cancer Genet Cytogenet 96:129-133.
21. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. 2005. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065-7070.
22. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. 2005. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 33:5394-5403.
23. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. 2004. Human MicroRNA targets. PLoS Biol 2:e363.
24. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. 2005. RAS is regulated by the let-7 microRNA family. Cell 120:635-647.
25. Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM. 1996. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med 41:483-490.
26. Klotzbucher M, Wasserfall A, Fuhrmann U. 1999. Misexpression of wild-type and truncated isoforms of the high-mobility group I proteins HMGI-C and HMGI(Y) in uterine leiomyomas. Am J Pathol 155:1535-1542.
27. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. 2001. Identification of novel genes coding for small expressed RNAs. Science 294:853-858.
28. Lehtonen R, Kiuru M, Vanharanta S, Sjoberg J, Aaltonen LM, Aittomaki K, Arola J, Butzow R, Eng C, Husgafvel-Pursiainen K, Isola J, Jarvinen H, Koivisto P, Mecklin JP, Peltomaki P, Salovaara R, Wasenius VM, Karhu A, Launonen V, Nupponen NN, Aaltonen LA. 2004. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol 164:17-22.
29. Levy B, Mukherjee T, Hirschhorn K. 2000. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. Cancer Genet Cytogenet 121:1-8.
30. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. 2003. Prediction of mammalian microRNA targets. Cell 115:787-798.
31. Ligon AH, Morton CC. 2001. Leiomyomata: Heritability and cytogenetic studies. Hum Reprod Update 7:8-14.
32. Luoto R, Kaprio J, Rutanen EM, Taipale P, Perola M, Koskenvuo M. 2000. Heritability and risk factors of uterine fibroids-The Finnish twin cohort study. Maturitas 37:15-26.
33. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, Willen WC, Hunter DJ. 1997. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 90:967-973.
34. Moore SD, Herrick SR, Ince TA, Kleinman MS, Cin PD, Morton CC, Quade BJ. 2004. Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF. Cancer Res 64:5570-5577.
35. Naraba H, Iwai N. 2005. Assessment of the microRNA system in salt-sensitive hypertension. Hypertens Res 28:819-826.
36. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Muller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E, Ruvkun G. 2000. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408:86-89.
37. Pron G, Mocarski E, Bennett J, Vilos G, Common A, Vanderburgh L. 2005. Pregnancy after uterine artery embolization for leiomyomata: The Ontario multicenter trial. Obstet Gynecol 105:67-76.
38. Rein MS, Powell WL, Walters FC, Weremowicz S, Cantor RM, Barbieri RL, Morton CC. 1998. Cytogenetic abnormalities in uterine myomas are associated with myoma size. Mol Hum Reprod 4:83-86.
39. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. 2000. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403:901-906.
40. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J. 2003. TM4: A free, open-source system for microarray data management and analysis. Biotechniques 34:374-378.
41. Sato F, Mori M, Nishi M, Kudo R, Miyake H. 2002. Familial aggregation of uterine myomas in Japanese women. J Epidemiol 12:249-253.
42. Shingara J, Keiger K, Shelton J, Laosinchai-Wolf W, Powers P, Conrad R, Brown D, Labourier E. 2005. An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA 11:1461-1470.
43. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. 2004. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64:3753-3756.
44. Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121.
45. Vanharanta S, Wortham NC, Laiho P, Sjoberg J, Aittomaki K, Arola J, Tomlinson IP, Karhu A, Arango D, Aaltonen LA. 2005. 7q deletion mapping and expression profiling in uterine fibroids. Oncogene 24:6545-6554.
46. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257-2261.
47. Wei JJ, Chiriboga L, Arslan AA, Melamed J, Yee H, Mittal K. 2006a. Ethnic differences in expression of the dysregulated proteins in uterine leiomyomata. Hum Reprod 21:57-67.
48. Wei JJ, Zhang XM, Chiriboga L, Yee H, Perle MA, Mittal K. 2006b. Spatial differences in biologic activity of large uterine leiomyomata. Fertil Steril 85:179-187.
49. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. 1994. Hysterectomy in the United States, 1988-1990. Obstet Gynecol 83:549-555.
50. Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, Rosenberg L. 2004. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: A prospective study. Am J Epidemiol 159:113-123.